In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I] 2/IC50 threshold

Drug Metabolism and Disposition

Volumn 42, Issue 2, 2014, Pages 257-263

  Kishimoto, Wataru ^a   Ishiguro, Naoki ^a   Ludwig Schwellinger, Eva ^b   Ebner, Thomas ^b   Schaefer, Olaf ^a  

^a NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BIBR 1087; CLARITHROMYCIN; CYCLOSPORIN A; DABIGATRAN ETEXILATE; DIGOXIN; DRUG METABOLITE; ITRACONAZOLE; KETOCONAZOLE; LINAGLIPTIN; MULTIDRUG RESISTANCE PROTEIN; NELFINAVIR; QUINIDINE; RITONAVIR; TACROLIMUS; UNCLASSIFIED DRUG;

[I]2/IC 50 RATIO; ARTICLE; CONTROLLED STUDY; DRUG INTERACTION; DRUG TRANSPORT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MATHEMATICAL ANALYSIS; MONOLAYER CULTURE; PHARMACOLOGICAL PARAMETERS; PREDICTION; PRIORITY JOURNAL; TRANSCYTOSIS; VALIDITY;

ANTITHROMBINS; BENZIMIDAZOLES; BIOLOGICAL TRANSPORT; CACO-2 CELLS; DIGOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; INTESTINES; LIVER; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PYRIDINES; RISK ASSESSMENT;

EID: 84891781401     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.053769     Document Type: Article

References (28)

1. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, and Gottesman MM (2003) P-glycoprotein: from genomics to mechanism. Oncogene 22:7468-7485. (Pubitemid 37487170)
2. Ayesh S, Shao YM, and Stein WD (1996) Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. Biochim Biophys Acta 1316:8-18. (Pubitemid 26174919)
3. Bentz J, O'Connor MP, Bednarczyk D, Coleman J, Lee C, Palm J, Pak YA, Perloff ES, Reyner E, and Balimane P, et al. (2013) Variability in P-glycoprotein inhibitory potency (IC50) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria. Drug Metab Dispos 41:1347-1366.
4. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, and Roth W (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36: 386-399. (Pubitemid 351185753)
5. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, and Kim RB (2000) Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28:655-660. (Pubitemid 30390404)
6. Cook JA, Feng B, Fenner KS, Kempshall S, Liu R, Rotter C, Smith DA, Troutman MD, Ullah M, and Lee CA (2010) Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies. Mol Pharm 7:398-411.
7. EMA (2012) Guideline on the Investigation of Drug Interactions. Final CPMP/EWP/560/95, European Medicines Agency, London.
8. Eberl S, Renner B, Neubert A, Reisig M, Bachmakov I, König J, Dörje F, Mürdter TE, Ackermann A, and Dormann H, et al. (2007) Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet 46: 1039-1049. (Pubitemid 350136910)
9. FDA (2012) Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Draft Guidance. US Food and Drug Administration, Silver Spring, MD (http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/default.htm).
10. Faessel HM, Burstein AH, Troutman MD, Willavize SA, Rohrbacher KD, and Clark DJ (2008) Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers. Eur J Clin Pharmacol 64:1101-1109.
11. Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, and Lee CA (2009) Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 85:173-181.
12. Friedrich C, Ring A, Brand T, Sennewald R, Graefe-Mody EU, and Woerle HJ (2011) Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. Eur J Drug Metab Pharmacokinet 36:17-24.
13. Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, and Sandmann S (2011) In vitro and in vivo Pglycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 338:372-380.
14. Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y, and Cheboyina S (2006) Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 34:69-74. (Pubitemid 43045694)
15. Gurley BJ, Swain A, Williams DK, Barone G, and Battu SK (2008) Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res 52:772-779.
16. Ishiguro N, Kishimoto W, Volz A, Ludwig-Schwellinger E, Ebner T, and Schaefer O (2013a) Impact of endogenous esterase activity on in vitro P-gp profiling of dabigatran etexilate in Caco-2 monolayers. Drug Metab Dispos 42:250-256.
17. Ishiguro N, Shimizu H, Kishimoto W, Ebner T, and Schaefer O (2013b) Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods. Drug Metab Dispos 41:149-158.
18. Jalava KM, Partanen J, and Neuvonen PJ (1997) Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 19:609-613. (Pubitemid 28046984)
19. Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, and Unadkat JD (2012) Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion. Drug Metab Dispos 40: 610-616.
20. Linagliptin (2010) Center for Drug Evaluation and Research NDA Application No. 201280Orig1s000. Boehringer Ingelheim Pharmaceuticals, Inc. 2010 July 2 (http://www. accessdata.fda.gov/drugsatfda-docs/nda/2011/ 201280Orig1s000ClinPharmR.pdf).
21. Mizuno N, Niwa T, Yotsumoto Y, and Sugiyama Y (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55:425-461. (Pubitemid 37013212)
22. Mueck W, Kubitza D, and Becka M (2013) Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 76:455-466.
23. Pedersen KE, Christiansen BD, Klitgaard NA, and Nielsen-Kudsk F (1983) Effect of quinidine on digoxin bioavailability. Eur J Clin Pharmacol 24:41-47. (Pubitemid 13181784)
24. Penzak SR, Shen JM, Alfaro RM, Remaley AT, Natarajan V, and Falloon J (2004) Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. Ther Drug Monit 26:322-330. (Pubitemid 38703022)
25. Rameis H (1985) Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? Int J Clin Pharmacol Ther Toxicol 23:145-153. (Pubitemid 15100828)
26. Schinkel AH and Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3-29. (Pubitemid 36078452)
27. Shirasaka Y, Sakane T, and Yamashita S (2008) Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci 97:553-565.
28. Stangier J, Stähle H, Rathgen K, Roth W, Reseski K, and Körnicke T (2011) Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin. J Clin Pharmacol 52:243-250.